17-N-Allylamino-17-demethoxygeldanamycin

From Wikipedia, the free encyclopedia

17-N-Allylamino-17-demethoxygeldanamycin
IUPAC name	[(3S,5S,6R,7S,8E,10R,11S,12E,14E)-21- (allylamino)-6-hydroxy-5,11-dimethoxy-3, 7,9,15-tetramethyl-16,20,22-trioxo-17- azabicyclo[16.3.1]docosa-8,12,14,18,21- pentaen-10-yl] carbamate
Identifiers
CAS number	[75747-14-7]
PubChem	6440175
SMILES	CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC (=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC
ChemSpider ID	21106220
Properties
Molecular formula	C31H43N3O8
Molar mass	585.689 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox references

17-N-Allylamino-17-demethoxygeldanamycin is a substance that is being studied in the treatment of cancer, specific young patients with certain types of leukemia or solid tumors, especially kidney tumors. As of June 2005, 17-N-allylamino-17-demethoxygeldanamycin is undergoing Phase 1 and Phase 2 clinical trials. It belongs to the family of drugs called antitumor antibiotics.

[edit] References

This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (September 2007)

[edit] External links

• Phase 1 trial
• Another Phase 1 trial
• National Cancer Institutie Bulletin on Phase 2 trials against Von Hippel-Lindau disease
• Safety sheet for 17AAG

This antibiotic-related article is a stub. You can help Wikipedia by expanding it.

This article about an organic compound is a stub. You can help Wikipedia by expanding it.